Navigation Links
Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
Date:8/6/2008

BioTime, Inc. (OTCBB:BTIM) announced today that Robert N. Butler, M.D., has been elected to BioTime’s Board of Directors. Dr. Butler is the founder, Chief Executive Officer, and President of the International Longevity Center-USA, a non-profit international research, policy, and education organization formed to educate individuals on how to live longer and better, and advise society on how to maximize the benefits of today's age boom. Dr. Butler received his B.A. degree from Columbia College in 1949 and a M.D. Degree from the College of Physicians and Surgeons of Columbia University in 1952. He was the founding director of the National Institute on Aging of the National Institutes of Health, and from 1975-1982 he led that institute educating the nation about the need for innovative therapies for Alzheimer’s disease. At the Mount Sinai School of Medicine, he founded the nation’s first department of geriatrics where he is Professor of Geriatrics and Adult Development. He is a member of the Institute of Medicine of the National Academy of Sciences and of the National Academy of Social Insurance. He was a member of the Physician Payment Review Commission, an agency of the U.S. Congress, from 1986-89. He is a founding Fellow of the American Geriatrics Society and vice chairman of the Alliance for Aging Research. He served as Chair, Advisory Committee, 1995, for the White House Conference on Aging. He was a member of the Advisory Committee for the Project on Death in America by the Open Society Institute. He has been a consultant to the U.S. Senate Special Committee on Aging, the Commonwealth Fund, the Brookdale Foundation, the Donald W. Reynolds Foundation and numerous other organizations. He has served on the National Advisory Committees of the Physicians for Human Rights, the National Women's Health Resource Center and the Mildred and Claude Pepper Foundation, among other organizations. He also served as medical editor-in-chief of Geriatrics, a journal for primary care physicians, for 14 years and has authored approximately 300 scientific and medical articles. Dr. Butler won the Pulitzer Prize for his book Why Survive? Being Old in America. His latest book is The Longevity Revolution.

ALAMEDA, Calif. (Business Wire EON) August 6, 2008 -- "The aging of the baby boom generation is the most significant demographic trend of our time," said Michael D. West, Ph.D., BioTime's Chief Executive Officer. "We look forward in working with Dr. Butler in focusing the emerging technologies of regenerative medicine on the large and growing markets in age-related degenerative disease."

  • Butler said, "It is exciting to be elected to the board of BioTime, an innovative company built for this era of longevity."

About BioTime, Inc. (BTIM.OB):

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend, PentaLyte, HetaCool, EmbryomicsTM, ESpyTM, and ESpanTM are trademarks of BioTime, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.


Read the full story at http://www.prweb.com/releases/biotime/butler/prweb1188094.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
2. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
3. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
6. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
7. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
8. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
9. Hiemstra Appoints Robert C. Glines as Director of Business Development
10. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
11. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 
(Date:8/23/2017)... ... August 23, 2017 , ... ... academic medical centers. The network provides members nationally scaled infrastructure and support to ... and restrictive payer agreements so members can provide continuity of care for their ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox has adapted their core ... to be provide scientists with easy to understand reports, extended indel analysis, and ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... The awards recognize medical centers that have implemented innovative products, services, and technology ... care protocols, competitive advantages, financial impact/value, and market need. The applicants with the ...
(Date:8/21/2017)... ... August 21, 2017 , ... The team at ... educational webinar, in which attendees will learn about the assembly and topological architecture ... with an overview of the development and validation of new high-quality recombinant monoclonal ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):